PURPOSE: A persistently elevated or rising serum level of prostate-specific antigen (PSA)
after radical prostatectomy is indicative of recurrent prostate cancer. The natural history of …

PURPOSE: For prostate cancer that is thought to be locally recurrent after prostatectomy, the
optimal timing, dose and techniques for salvage radiotherapy (SRT) have not been …

Background Radiotherapy is the standard salvage treatment after radical prostatectomy. To
date, the role of androgen deprivation therapy has not been formally shown. In this follow-up …

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of
recurrent prostate cancer among patients treated with radical prostatectomy. Salvage …

Purpose To describe outcomes of salvage radiotherapy (SRT) for men with detectable
prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify …

Context Biochemical disease recurrence after radical prostatectomy often prompts salvage
radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to …

ContextSalvage radiotherapy may potentially cure patients with disease recurrence after
radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at …

Purpose: Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate
specific antigen (PSA) only recurrence (PSAR), however, there is virtually no published …

BACKGROUND: Previous randomised trials demonstrated that adjuvant radiation therapy
(aRT) improves cancer control in patients with pT3 prostate cancer (PCa). However, there is …

Background Early salvage radiotherapy (eSRT) represents the only curative option for
prostate cancer patients experiencing biochemical recurrence (BCR) for local recurrence …